secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-01-18T23:59:59+00:00
Accession:  0001140361-24-002636
Event type: debt
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 1.02, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio secures $500M royalty financing for acoramidis and $450M term loan, repays existing debt
--------------------------------------------------------------------------------

- Funding Agreement: $500M from LSI/CPPIB upon FDA approval of acoramidis; 5% royalty on global net sales, cap $950M.
- Financing Agreement: $450M initial term loan funded (up to $300M incremental) from Blue Owl; SOFR+6.75% or base+5.75% interest; matures Jan 17, 2029.
- Existing $450M loan from Nov 2021 repaid and terminated using initial term loan proceeds and cash on hand.
- Minimum cash covenant of $70M; prepayment fees up to 3% plus make-whole; two springing maturities tied to convertible notes.
- Funding terminates if FDA approval of acoramidis does not occur by May 15, 2025, with no penalty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124002636/0001140361-24-002636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124002636/ef20019054_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-002636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer